Can stem cell vesicles help rebuild brain blood vessels in moyamoya?

NCT ID NCT07065409

Recruiting now Disease control Sponsor: Huaqiu Zhang Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new treatment for Moyamoya disease, a rare condition where major brain arteries narrow, raising stroke risk. The treatment combines a special muscle flap with injections of tiny particles from stem cells (iPSC-EVs) to encourage new blood vessel growth. Nine adults will be monitored for safety and early signs of improved blood flow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iPSC-derived extracellular vesicles (iPSC-EVs)
What this could lead to: If successful, this could lead to a new way to help the brain grow new blood vessels in Moyamoya disease, potentially reducing stroke risk.
What could go wrong: This is a very early phase 1 trial with only 9 participants, focused on safety. It is too small to prove effectiveness, and the treatment may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MOYAMOYA DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Moyamoya disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MOYAMOYA DISEASE

Contacts and locations

Locations

Tongji hospital
RECRUITING

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.